David O. Sussman DO, FACOS

Our Doctors

David O. Sussman, DO, FACOS


Urology/Incontinence & Voiding/Erectile Dysfunction


Benign Prostatic Hypertrophy
Male/Female Incontinence
Pelvic Proclapse/Pelvic Reconstruction
Erectile Dysfunction
Penile Prsthetics
Overactive Bladder
Neurogenic Bladder
Female Urology
Male Hernia Surgery

Board Certifications

American Osteopathic Board of Surgery


Franklin and Marshall College

Medical School

University of New England


University of Medicine and Dentistry of NJ


University of Medicine and Dentistry of NJ


Kaiser Permanente/Albert Einstein College of Medicine

Years in Practice

since 1992

Diseases and Conditions

Practice Location(s)

Delaware Valley Urology

777 S. White Horse Pike
Suite C-1
Hammonton, NJ 08037
TEL: 609.481.4068
FAX: 856.267.2499

570 Egg Harbor Road
Suite A-1
Sewell, NJ 08080-2359
TEL: 856.582.9645
FAX: 856.985.4583

2401 East Evesham Road
Suite F
Voorhees, NJ 08043
TEL: 856.673.1600
FAX: 856.988.0636

Hospital Affiliation(s)

Washington Township



American College of Osteopathic Surgeons
American Urologic Association
American Osteopathic Association
Camden County Society of Osteopathic Physicians and Surgeons
Philadelphia Urology Society
Urology Society of New Jersey
International Continence Society
Society for Urodynamics and Female Urology

Research and Publications


Principle Investigator - Finasteride (MK-906), MErck & Company, 1994-1998, PLESS Study
Reviewer - Agency for HEalth Care Policy and REsearch, Benign Prostatic Hypertrophy       Guidelines
Co-Investigator - BCG/INTRON Bladder Cancer Study, 1999-2001
Principle Investigator - Detrol Quality of Life  Study, 2001
Principle Investigator - Detrol Nocturia Study, "NITE", 2002
Principle Investigator - SLT Trial for Benign Prostatic Hypertrophy, 2002
Principle Investigator - Tamsulosin Trial-Treatment of Acute Urinary Retention, 2002
Principle Investigator - Neurogenic OAB Botox Trial, Beginning February 2007
Principle Investigator - Fesoterodine in the Frail Elderly, Beginning in September 2009
Principle Investigator - Idiopathic OAB/Botox, Beginning in November 2009


Perforated Sigmoid Diverticulitis: Case Report and Literature Review-June 1987

Renal Liposarcoma: Case  Report and Literature Review-June 1988

Squamous Cell Carcinoma in a Female Urethral Diverticulum-June 1990

Stage C Prostate Carcinoma: Total Androgen Ablation Prior to Radical Retropubic Prostatectomy-Poster Presentation-ACOS Annual Meeting-October 1990

Penile Prosthetic InfectionsUtilizing the Surgical Isolation Bubble System (SIBS)-June 1991

Current Operative Approaches to Benign Prostatic Hyperplasia-The Journal-NJAOPS-December 1991

Treatment Options for Benign Prostatic Hyperplasia-N.J. Journal-NJAOPS-December 1991

The Urologist' Role in the Evaluation of the Infertile Couple-The Journal-NJAOPS-December 1991

Editor-The Journal-NJAOPS-December 1991

Treatment of Caculus Disease in the 90's-Co-Author-The Journal-NJAOPS-December 1992

In-Situ Vesical Wall Sling (Vesica) For the Treatment of Stress Urinary Incontinence-The Journal-NJAOPS-May 1997

Poster Presentation-ACET Trial-ACOS Convention, Orlando, Florida-2002

Poster Presentation-PVS/Cystocele Repair-ACOS Convention, Orlando, Florida-2002

Poster Presentation-PVS Repair-Repliform-ACOS Convention, Orlando, Florida-2002

Poster Presentation-ACET Trial-European Association of the Urology-Birmingham, England-2002

Sussman D., Garely A. Treatment of Overactive Bladder with Once-daily Extended-release Tolterodine or Oxybutinin: The Antimuscarinic Clinical Effectiveness Trial (ACET), Current Medical Research Opinion 2002:18(4);177-1

Sussman, D. Pharmacokinetics, Pharmacodynamics and Efficacy of Phosphodiesterase Type 5 Inhibitors. JAOA. Supplement 4. 2004;104:S11-15

Brown, GA., Sussman, DO. A Current Review of MEdical Therapy for Benign Prostatic Hyperplasia. JAOA Supplement 2. 2004;104: S11-16

Poster Presentation-Dry mouth was more pronounced in patients with overactive bladder treated with extended-release oxybutinin compared to tolterodine. European Association of Urology-Istanbul, Turkey 2004

Poster presentation-The tolerability of tolteroodine is not diminished in older patients with overactive bladder: An analysis of 5 randomized, double-blind placebo controlled trials. 64th Annual Meeting of the Mid-Atlantic Section of the AUA. Washington, D.C. 2006

Poster Presentation-Effects of Tolterodine Extended release and/or tamsulosin on bladder Diary variables and patient-reported outcomes in men with lower urinary tract symptoms Including OAB European Association of Urology-Berlin, Germany 2007

Sussman, David O., Kraus, Stephen R. Onset of Efficacy of Tolterodine Extended Release In patients with overactive bladder, Current Medical Research and Opinion 2007:23(4) 777-781

Sussman, David O. Overactive Bladder:Treatment Options in Primary Care Medicine. J. Am Osteopathic Assoc 2007;107(9):379-385

Ronver, ES, Kreder, K, Sussman, DO, Kaplan, SA, Carlsson, M et al. Effect of Tolterodine Extended Release with or without Tamsulosin on Measures of Urgency and Patient Reported Outcomes in Men with Lower Urinary Tract Syptoms. J. Urology 2008; 1034-1041

Sussman, D., Patel, V., Del Popolo. G/. Lam, W., Globe, D.,  Pomerville, P/. Treatment Satisfaction and Improvement in Health Related Quality of Life with Onabotulinumtoxin A in Patients with Urinary Incontinence Due to Neurogenic Detrussor Overactivity. Accepted for Publication Neurology and Urodynamics 2013

Poster Presentation-Nitti, V., Chapple, C., Sand, P., Sussman, D., et al. OnabotulinumtoxinA in Patients with Overactive Bladder and Urinary Incontinence: Consistent Effect Over Repeated Treatment-Accepted AUA 2013 San Diego, CA

Nitti V, Sievert K, Chapple C, Sussman D, et al. Clinically Meaningful Improvements in urinary Incontinence and Quality of Life Over Multiple Treatment Cycles of OnabotulinumtoxinA in Patients with OAB syndrome and Urinary Incontinence: Interim Analysis of as Long Term Extension Study. ICS abstract. barcelona, Spain 2013

Sand P,, Egerdie B, Sussman D, etal. Greater Improvement in health Related Quality of Life after OnabotulinumtoxinA Treatment are Associated with Greater Reduction in Urinary Incontinence in Patients with OAb syndrome: Results from Two Phase 3 Studies. ICS abstract. Barcelona, Spain 2013


Awards and Honors

Reader's Choice-South Jersey's Best Physicians 2013
South Jersey Magazine Readers Choice